Our candidate medicines provide the opportunities to cure and modify diseases, and to address the unmet medical needs of patients and their carers.

Our programmes

Our liver-focused pipeline is currently built around three principal areas of high unmet need: haematology, metabolic and rare diseases. We also apply a patient-friendly delivery technology suitable for applications in a variety of disease settings.

Pipeline_D_Our Programmes_Dark@2x.png _PipelineMaster_v11_Pipeline_M_Our Programmes_Dark.png

Out-licensed programmes

We have out-licensed our siRNA stabilisation chemistry technology (AtuRNAiTM) to Quark Pharmaceuticals, who have progressed drug candidates that use this technology in late-stage clinical trials.

Pipeline_D_Out-Licensed_Dark@2x.png Pipeline_M_Out-Licensed_Dark@2x.png

Please click the licensee programme names below to view our factsheets.

  • pipeline-logo1.png
  • pipeline-logo2.png